ResearchMoz.us include new market research report"Anti-Hypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries " to its huge collection of research reports.
GBI Research, the leading business intelligence provider, has released its latest research: ‘Anti-Hypertensive Therapeutics in Major Developed Markets to 2020 – Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries ’, which provides in-depth analysis of hypertension therapeutics market within the eight major geographies of the US, the top five European countries (the UK, France, Germany, Spain and Italy), Japan and Canada.
Full Report With TOC @ http://www.researchmoz.us/anti-hypertensive-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-combination-therapies-to-offset-effects-of-key-patent-expiries-report.html
The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The value of the hypertension market in the major developed markets amounted to an estimated $40.0 billion in 2013 and is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017.
All Latest Market Research Report @ http://www.researchmoz.us/latest-report.html
Scope
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the hypertension in the major developed markets.
The report includes:
Disease overview, as well as treatment algorithms and treatment use patterns
Market size and forecast for the hypertension market from 2013–2020
Major marketed products for hypertension along with a heat map of product performance
In-depth pipeline analysis for global pipeline in hypertension along with clinical trial failure rate analysis
Key drivers and restraints that have had and are expected to have a significant impact upon the market
Key licensing and co-development agreements that could have impact on growth trends
Reasons to Buy
The report will enhance your decision-making capability by allowing you to:
Align your product portfolio to the markets with high growth potential
Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
All Countrywise Report @ http://www.researchmoz.us/country.html
Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the hypertension therapeutics market
Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
For More Information Kindly Contact:
Email: sales@researchmoz.us
WebSite:http://www.researchmoz.us/
0 comments:
Post a Comment